BrightAccountsProduction v1.0.0 v1.0.0 2025-01-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principal activity of the company is the provision of services to compliment patient centered care 10 September 2026 NI642637 2025-12-31 NI642637 2024-12-31 NI642637 2023-12-31 NI642637 2025-01-01 2025-12-31 NI642637 2024-01-01 2024-12-31 NI642637 uk-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 NI642637 uk-curr:PoundSterling 2025-01-01 2025-12-31 NI642637 uk-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 NI642637 uk-bus:FullAccounts 2025-01-01 2025-12-31 NI642637 uk-bus:Director1 2025-01-01 2025-12-31 NI642637 uk-bus:RegisteredOffice 2025-01-01 2025-12-31 NI642637 uk-bus:Agent1 2025-01-01 2025-12-31 NI642637 uk-core:ShareCapital 2025-12-31 NI642637 uk-core:ShareCapital 2024-12-31 NI642637 uk-core:RetainedEarningsAccumulatedLosses 2025-12-31 NI642637 uk-core:RetainedEarningsAccumulatedLosses 2024-12-31 NI642637 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2025-12-31 NI642637 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-12-31 NI642637 uk-bus:FRS102 2025-01-01 2025-12-31 NI642637 uk-core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 NI642637 uk-core:CurrentFinancialInstruments 2025-12-31 NI642637 uk-core:CurrentFinancialInstruments 2024-12-31 NI642637 uk-core:WithinOneYear 2025-12-31 NI642637 uk-core:WithinOneYear 2024-12-31 NI642637 uk-core:WithinOneYear 2025-12-31 NI642637 uk-core:WithinOneYear 2024-12-31 NI642637 uk-core:BetweenOneTwoYears 2025-12-31 NI642637 uk-core:BetweenOneTwoYears 2024-12-31 NI642637 2025-01-01 2025-12-31 NI642637 uk-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Screen Clinical Limited
 
Unaudited Financial Statements
 
for the financial year ended 31 December 2025



Screen Clinical Limited
DIRECTOR AND OTHER INFORMATION

 
Director Michael O'Neill
 
 
Company Registration Number NI642637
 
 
Registered Office and Business Address 16 Tobermore Road
Draperstown
Magherafelt
BT45 7HG
 
 
Accountants Quarter
Chartered Accountants
St.Annes House
Cathedral Quarter
15 Church Street
Belfast
County Antrim
BT1 1PG
United Kingdom



Screen Clinical Limited
Company Registration Number: NI642637
STATEMENT OF FINANCIAL POSITION
as at 31 December 2025

2025 2024
Notes £ £
 
Non-Current Assets
Intangible assets 4 8,550 -
Property, plant and equipment 5 58,866 62,101
───────── ─────────
Non-Current Assets 67,416 62,101
───────── ─────────
 
Current Assets
Receivables 6 247,069 379,891
Cash and cash equivalents 163,239 34,328
───────── ─────────
410,308 414,219
───────── ─────────
Payables: amounts falling due within one year 7 (339,048) (312,024)
───────── ─────────
Net Current Assets 71,260 102,195
───────── ─────────
Total Assets less Current Liabilities 138,676 164,296
 
Payables:
amounts falling due after more than one year 8 (90,544) (116,120)
───────── ─────────
Net Assets 48,132 48,176
═════════ ═════════
 
Equity
Called up share capital 100 100
Retained earnings 48,032 48,076
───────── ─────────
Equity attributable to owners of the company 48,132 48,176
═════════ ═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
           
The company has taken advantage of the exemption under section 444 not to file the Income Statement and Director's Report.
           
For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The director acknowledges his responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Director and authorised for issue on 10 September 2026
           
           
________________________________          
Michael O'Neill          
Director          
           



Screen Clinical Limited
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

   
1. General Information
 
Screen Clinical Limited is a company limited by shares incorporated and registered in Northern Ireland. The registered number of the company is NI642637. The registered office of the company is 16 Tobermore Road, Draperstown, Magherafelt, BT45 7HG which is also the principal place of business of the company. The principal activity of the company is the provision of services to compliment patient centered care The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Revenue
Revenue comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Intangible assets
Intangible assets are valued at cost less accumulated amortisation and impairment losses. Amortisaton is charged on a straight-line basis over 5 years, reflecting the prudent estimate of the asset's useful economic life.
 
Property, plant and equipment and depreciation
Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:
 
  Fixtures, fittings and equipment - 20% Reducing Balance
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
Leasing
Rentals payable under operating leases are dealt with in the Income Statement as incurred over the period of the rental agreement.
 
Trade and other receivables
Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Borrowing costs
Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
 
Trade and other payables
Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company contributes to a stakeholder pension scheme on behalf of its employees
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

 
Government grants
Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
       
3. Employees
 
The average monthly number of employees, including director, during the financial year was 21, (2024 - 21).
 
  2025 2024
  Number Number
 
Director 1 1
Employee 20 20
  ───────── ─────────
  21 21
  ═════════ ═════════
       
4. Intangible assets
     
    Total
  £ £
Cost
At 1 January 2025 - -
Additions 8,550 8,550
  ───────── ─────────
At 31 December 2025 8,550 8,550
  ───────── ─────────
Amortisation
At 1 January 2025 - -
  ───────── ─────────
Carrying amount
At 31 December 2025 8,550 8,550
  ═════════ ═════════
At 31 December 2024 - -
  ═════════ ═════════
       
5. Property, plant and equipment
  Fixtures, Total
  fittings and  
  equipment  
  £ £
Cost
At 1 January 2025 97,636 97,636
Additions 10,957 10,957
  ───────── ─────────
At 31 December 2025 108,593 108,593
  ───────── ─────────
Depreciation
At 1 January 2025 35,535 35,535
Charge for the financial year 14,192 14,192
  ───────── ─────────
At 31 December 2025 49,727 49,727
  ───────── ─────────
Carrying amount
At 31 December 2025 58,866 58,866
  ═════════ ═════════
At 31 December 2024 62,101 62,101
  ═════════ ═════════
       
6. Receivables 2025 2024
  £ £
 
Trade receivables 231,058 358,681
Other debtors 5,000 5,000
Deferred tax asset 6,426 16,210
Prepayments and accrued income 4,585 -
  ───────── ─────────
  247,069 379,891
  ═════════ ═════════
       
7. Payables 2025 2024
Amounts falling due within one year £ £
 
Bank overdrafts - 28,321
Trade payables 9,833 -
Taxation  (Note 9) 67,797 135,896
Director's current account 125,814 95,555
Other creditors 96,418 16,300
Accruals 39,186 35,952
  ───────── ─────────
  339,048 312,024
  ═════════ ═════════
       
8. Payables 2025 2024
Amounts falling due after more than one year £ £
 
Other long term loan 90,544 116,120
  ═════════ ═════════
 
Loans
Repayable in one year or less, or on demand (Note 7) - 28,321
Repayable between one and two years 90,544 116,120
  ───────── ─────────
  90,544 144,441
  ═════════ ═════════
 
       
9. Taxation 2025 2024
  £ £
 
Payables:
VAT 32,104 32,694
PAYE / NI 35,693 103,202
  ───────── ─────────
  67,797 135,896
  ═════════ ═════════
       
10. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 December 2025.
   
11. Director's advances, credits and guarantees
 
As at 31.12.2024 Screen Clinical Limited owed directors £95,555. During the year, there was a net movement of £30,259 between Screen Clinical Limited and directors. As at 31.12.2025 Screen Clinical Limited owed directors £125,814.
   
12. Events After the End of the Reporting Period
 
There have been no significant events affecting the company since the financial year-end.